A Biorepository for Coronary Heart Disease in Qatar (QCBio)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03427489
Recruitment Status : Recruiting
First Posted : February 9, 2018
Last Update Posted : February 9, 2018
Mayo Clinic
Information provided by (Responsible Party):
Dr. Ayman El-Menyar, Hamad Medical Corporation

Brief Summary:

Coronary heart disease (CHD) poses a major health burden in the Gulf countries. It is the leading cause of mortality and morbidity in the world and poses an enormous societal burden in the Gulf countries. Early detection of disease is imperative to reduce the health care burden and financial costs associated with CHD. Knowledge of novel genetic and proteomic markers of CHD will provide more precise estimates of risk while defining the pathways important in individual patients, revealing new targets for intervention, and ultimately enabling an individualized approach to care.

To translate recent advances in genomics and proteomics into clinical practice, these newly discovered biomarkers will need to be evaluated in patients of diverse ethnic groups with varying characteristics, environmental factors, and medication use. The investigators propose to establish a biorepository of plasma and Deoxyribonucleic acid (DNA) linked to demographic and clinical variables to facilitate biomarker studies of CHD risk, progression, and outcome. The overarching goal in developing the Qatar Cardiovascular Biorepository (QCBio) is to create a resource that fosters research aimed at identifying novel biochemical and genetic markers of CHD. A biorepository with linkage to clinical data will also provide an invaluable resource for cardiovascular research, including genomic and proteomic studies of CHD and development of biomarkers for early detection of disease and personalized drug therapy (pharmacogenetics and pharmacoproteomics).

Condition or disease
Coronary Heart Disease (CHD)

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 2000 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: A Biorepository for Discovering Novel Biochemical and Genetic Markers of Coronary Heart Disease in Qatar (QCBio)
Actual Study Start Date : January 31, 2013
Estimated Primary Completion Date : March 31, 2018
Estimated Study Completion Date : May 18, 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Coronary heart disease
Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.

Primary Outcome Measures :
  1. Identification of genetic variants associated with CHD in Qatari Individuals using whole genome sequencing on the 2000 samples stored at the genetic biorepository over 3 years. [ Time Frame: Three years ]
    QCBio will create an unparalleled and unique resource for conducting genomic and studies to identify and validate biomarkers for diagnosis, prognostication, and response to therapy, in Qataris patients who have CHD or at risk

Secondary Outcome Measures :
  1. Identification of circulating markers using plasma proteomic and metabolomic analysis in 2000 Qatari individuals with and without CHD. [ Time Frame: Three years ]
    Candidate approach with markers in etiologic pathways of atherosclerosis including inflammation, lipids, hemodynamic regulation, thrombosis and metabolism in addition to Agnostic approach using plasma metabolomics

Biospecimen Retention:   Samples With DNA
We intend to establish a DNA and plasma repository of 1000 Qatari CHD cases and 1000 ethnicity-matched controls (QCBio) to enable investigation of genomic and proteomic biomarkers for early detection and prognostication and to identify new targets for drug development.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population

Qatari individuals who present with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects from the coronary catheterization laboratory (Cath Lab) and the coronary care unit.

Ethnicity-matched controls are being recruited from the blood bank where individuals typically undergo screening by means of questionnaires and those with chronic or infectious disease are excluded.


Inclusion Criteria:

  • Subjects: History or clinical diagnosis of Acute Coronary Syndrome
  • Controls: No history of Coronary Heart disease.

Exclusion Criteria:

  • Chronic or infectious disease
  • Vulnerable populations (Children, prisoners, cognitive impairment)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03427489

Contact: Ayman El-Menyar, MD +974-44394029
Contact: Jassim Al-Suwaidi, MD

Hamad Medical Corporation Recruiting
Doha, Qatar, 3050
Contact: Ayman El-Menyar, MD    +974-44394029   
Sponsors and Collaborators
Hamad Medical Corporation
Mayo Clinic
Principal Investigator: Iftikhar Kullo Mayo Clinic College of Medicine
Principal Investigator: Ayman El-Menyar Hamad Medical Corporation
Principal Investigator: Jassim Al Suwaidi Hamad Medical Corporation


Responsible Party: Dr. Ayman El-Menyar, Associate Professor, Hamad Medical Corporation Identifier: NCT03427489     History of Changes
Other Study ID Numbers: NPRP No. : 5 - 1024 - 3 - 225
First Posted: February 9, 2018    Key Record Dates
Last Update Posted: February 9, 2018
Last Verified: February 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dr. Ayman El-Menyar, Hamad Medical Corporation:
Genetic Markers

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases